AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01682824 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete TFEQ-R18v2 questionnaire
Study NCT01682824 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete EQ-EMA questionnaire
Study NCT02276963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which induces immune response that causes lysis of B cells.
Study NCT02766348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks
Study NCT02766348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks
Study NCT02766348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CTL
Description: 8×10\^9 DC-CTL cells for each infusion, IV(In the vein) for 3 cycles, each cycle received four infusions on day 14,16,30 and 32
Study NCT02766348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatinum
Description: cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
Study NCT02766348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatinum
Description: cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
Study NCT03049826 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional status
Description: Body composition and nutrient status
Study NCT02151357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCBCI0901
Description: DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
Study NCT01302405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRI-724
Description: Dose escalation
Study NCT03745053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xlimus DES Implantation during coronary angioplasty
Description: Xlimus DES Implantation during coronary angioplasty
Study NCT03745053 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synergy DES Implantation during coronary angioplasty
Description: Synergy DES Implantation during coronary angioplasty
Study NCT00707044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group (usual care)
Description: control group, care as usual, 24 hours intensive care stay
Study NCT00707044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short-Stay Intensive Care treatment (SSIC)
Description: Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
Study NCT03787823 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: robotic Prostatectomy (RARP)
Description: Modification of robotic Prostatectomy Arm A classic technique/ anterior transperitoneal RARP Arm B Transdouglas Technique/retzius-sparing RARP
Study NCT03634943 — intervention group
Intervention type: OTHER
Intervention: Patients with Nutritional Support
Description: Evaluation of Enteral Nutrition or Parenteral Nutrition or both administered to the patients needing artificial Nutritional Support
Study NCT03582384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocofersolan
Description: After baseline labs are obtained, therapy with tocofersolan will be initiated at an initial dose of 17 mg/kg of d-alpha-tocopherol in the form of tocofersolan (0.34 ml/kg/day) and titrated based on blood levels.
Study NCT00179140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplementation
Description: oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat
Study NCT00179140 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: either before or during hemodialysis, patients will perform a leg press exercise; every other day, 3 days per week, for 6 months
Study NCT01576575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Control
Description: Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)
Study NCT01576575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine + Rifampin
Description: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine
Study NCT01576575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine + Grapefruit juice
Description: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine
Study NCT01576575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine + Ketoconazole
Description: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine
Study NCT02339103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed IV fluids
Description: 1 Liter of warmed IV fluids at 42 degrees celsius
Study NCT02339103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed perfusion pads
Description: Neoprene perfusion pads placed on the palms and soles to rewarm through focusing on the arteriovenous anastomoses
Study NCT03107910 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stigma and Structural Interventions
Description: Stigma focused counseling to address HIV anticipated stigma and online video chatting for HIV/STI testing will be assessed. Stigma and Structural Interventions
Study NCT03107910 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Information Seeking
Description: Seeking and evaluating online health information will be assessed.
Study NCT02592447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy for Targeted Therapy-related Fatigue (TTF)
Description: Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) group will receive cognitive behavior therapy to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions. The sessions will initially be held weekly, but the therapist may schedule sessions at 1-, 2-, or 3-week intervals during the 18 week study period. The final session will be conducted either in-person at Moffitt or via FaceTime.
Study NCT02592447 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-List Control Condition (WLC)
Description: Participants randomized to Wait-List Control Condition will continue to receive care under direction of their Moffitt Cancer Center (MCC) physician. Physicians will be informed by email of patients' participation on the basis of elevated fatigue and their randomization to WLC. Chart review and a patient self-report form will be used at baseline and follow-up assessments to determine what, if any, services or interventions participants received in the preceding 18 weeks that might address fatigue.
Study NCT04536363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analogs, Prostaglandin E1
Description: Analog of PGE1:~Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min.~If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days
Study NCT04536363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapeutic protocol
Description: Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~1. Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~2. Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~6. Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours
Study NCT04536363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapeutic protocol
Description: Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~1. Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~2. Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~6. Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours
Study NCT04581434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Prolonged Exposure Therapy is an individually-delivered treatment for PTSD that includes in vivo exposure to trauma reminders and imaginal exposure to the trauma memory delivered in 90-minute weekly sessions.
Study NCT04581434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Cognitive Processing Therapy is an individually-delivered treatment for PTSD that focuses on challenging and modifying maladaptive beliefs related to the trauma, with an optional written trauma account during weekly 60-minute sessions
Study NCT04581434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Present Centered Therapy
Description: Present Centered Therapy is an individually-delivered treatment for PTSD that focuses on current life problems as manifestations of PTSD in weekly 60-minute sessions. It includes psychoeducation and normalization of responses to trauma, problem solving related to current life difficulties and stress identified by patients, and emotional support and validation
Study NCT03981471 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Elderly people with or without fall history receive exercise to improve balance. Exercise interevention will be given 6 months in 2020. Outcomes (incidence of fall and biological tests) between two arms will be compared.
Study NCT00943852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: Single dose losartan 100 mg in one of five treatment periods
Study NCT00943852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: isosorbide mononitrate (ISMN)
Description: Single dose ISMN 60 mg in one of five treatment periods
Study NCT00943852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: losartan + ISMN
Description: Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
Study NCT00943852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: losartan + ISMN
Description: Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
Study NCT00943852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Single dose placebo only in one of five treatment periods
Study NCT03430180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone hydrochloride
Description: Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
Study NCT03430180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
Study NCT03881982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PIMPERNEL Novel Electronic Log: Pain display can be seen
Description: Pain scores are displayed on the screen when the participant presses the corresponding button
Study NCT03881982 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PIMPERNEL Novel Electronic Log: Pain display is hidden
Description: Participants press the buttons to record their pain score but the score is not on display (the screen is turned backwards).
Study NCT01661608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using the EOS for gastric restriction
Study NCT02897505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Workshop
Description: At each music workshop, the study staff will collect participants' pre- and post-session Physiological and Emotional Thermometer Surveys. The pre-session survey will be conducted prior to the start of the music workshop, and the post-session survey will be conducted within 15 minutes after the conclusion of the workshop.
Study NCT04579783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Group A: 40mg triamcinolone acetonide (1mL) + 4mL normal saline
Study NCT04579783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 5% in water
Description: Group B: 5mL 5% dextrose
Study NCT02742402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic imaging
Description: Abdominal ultrasound, followed by abdominal computed tomography when necessary
Study NCT02742402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Observation for 6 to 8 hours. After observation period repeated clinical examination and repeated blood test for calculation of Adult Appendicitis Score is done.
Study NCT03064113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03064113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 700 μg
Study NCT03064113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 350 μg
Study NCT03064113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium 500 μg
Study NCT00637403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Megestrol acetate concentrated suspension 125 mg/mL
Description: Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr >80 mL/min)
Study NCT00637403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate concentrated suspension 125 mg/mL
Description: Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)
Study NCT00637403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate concentrated suspension 125 mg/mL
Description: Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - \<50 mL/min)
Study NCT00637403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate concentrated suspension 125 mg/mL
Description: Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr \<30 mL/min and not on hemodialysis)
Study NCT00637403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate concentrated suspension 125 mg/mL
Description: Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
Study NCT02228005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Protocolized titration from 50 to max 200mg based on response and tolerance.
Study NCT01042418 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effect of breakfasts with whole vs milled rye kernels on appetite
Description: Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
Study NCT01042418 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Effect of breakfasts with whole vs milled rye kernels on appetite
Description: Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
Study NCT01042418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of breakfasts with whole vs milled rye kernels on appetite
Description: Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
Study NCT03708471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid ablation
Description: This intervention including thoracoscopic surgical ablation, percutaneous catheter ablation and cardiovascular risk control.
Study NCT03708471 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic surgical ablation
Description: This intervention including thoracoscopic surgical ablation and cardiovascular risk control.
Study NCT03089476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluating atopy in infants
Description: This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
Study NCT03089476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluating TEWL and STS in adults
Description: This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
Study NCT00532545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide 20 micrograms/daily subcutaneously
Study NCT01831869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-thyroxine
Study NCT03108612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Análisis de carga de trabajo (ACT)
Description: Semi-structured interview for detecting possible occupational etiology of an upper limb musculoskeletal disease that has been reported (by the worker) as possibly of occupational origin. The instrument is called Workload Analysis Instrument (WAI) or Análisis de Carga de Trabajo (ACT).
Study NCT01023204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
Study NCT00297648 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Certolizumab pegol (CDP870) 400 mg administered subcutaneously (sc) at Weeks 0, 2 and 4 (induction doses), then every 4 weeks (Q4W) until Week 52. Investigators can escalate dosage to CDP870 400 mg 2-weekly (Q2W) at any time after Week 10 for lack of response/remission. After Week 52 patients can continue to receive treatment until study drug end, either Q4W or Q2W, according to their administration frequency at Week 52.
Study NCT02882334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Finger Force Manipulandum
Study NCT02882334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Study NCT04060953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-Related Quality of Life Report
Description: Subject report and interpretation guide based on SPADE cluster scores
Study NCT02277353 — intervention group
Intervention type: OTHER
Intervention: Fluid loading to evaluate fluid responsiveness
Description: loading of hydroxyethyl starch 6ml/kg over 10-15min to all patients
Study NCT01346332 — intervention group
Intervention type: DEVICE
Intervention: Iontophoresis System with Headset
Description: Iontophoresis of an anesthesia solution to the tympanic membrane using the Acclarent Iontophoresis System with Headset
Study NCT02127606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration with tilt-table standing
Study NCT00954967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
Study NCT00750802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6280
Description: 10mg Capsule, oral, single-dose
Study NCT00750802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6280
Description: 40mg Capsule, oral, single-dose